The start of the next EULAR Annual European Congress of Rheumatology is fast approaching and is set to take place 8-11 June 2016 in London. I invite you to read about the wide range of sessions, activities, and events available to you at this year’s congress in the EULAR Congress News Preview Edition.
We look forward to welcoming you to the “world city” of London as an excellent background for a truly unique occasion of clinical exchange, international collaboration, and renewal of friendships. EULAR congresses have grown rapidly in terms of the number of participants and the quality of the submissions. We are expecting around 14,000 patients, physicians, scientists, health professionals, and professionals representing the pharmaceutical industry, from more than 100 countries in Europe and around the world, to participate, making this 17th EULAR congress one of the best attended in our history.
The number of scientific contributions to the EULAR congress remains at a very high level, this year again reaching more than 4,000 abstracts submitted, with 56% accepted for presentation and another 27% for publication.
This year’s congress will once again provide a wide range of topics including clinical innovations, clinical translational research, and basic science. In addition, there will be significant contributions made by People with Arthritis and Rheumatism in Europe (PARE), by Health Professionals in Rheumatology (HPR), and by the healthcare industry. Of the nearly 2,000 poster displays spread over 3 days, almost 500 will be explained in 45 themed poster tours. In addition, the EULAR 2016 Congress will mark a record with regard to the presentation of new recommendations concerning important topics such as early forms of arthritis as well as the management of rheumatoid arthritis, spondyloarthritis, and fibromyalgia. These recommendations reflect the enormous efforts of the EULAR members in helping to improve patient care.
It is our great pleasure and a real joy to welcome medical doctors, patients, health professionals, and representatives of the pharmaceutical industry, and we wish you all a delightful, informative, and educational stay in London.
Prof. Gerd R. Burmester
President of EULAR